Who is sponsoring NCT05547516?

NCT05547516 is sponsored by First Affiliated Hospital Xi'an Jiaotong University.

What drugs are being tested in NCT05547516?

Interventions in NCT05547516: Standard infusion chemotherapy, BL - 5 ala PDT.

What condition does NCT05547516 study?

NCT05547516 studies Non-muscle-invasive Bladder Cancer.

Is NCT05547516 still recruiting?

NCT05547516 is currently status unknown. Last updated 21 September 2022.

Last reviewed 2022-09-21 · How we verify

NCT05547516: BL-PDT-RCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Status unknown NA Last updated 21 September 2022

What this trial tests

NA trial testing Standard infusion chemotherapy in Non-muscle-invasive Bladder Cancer in 140 participants. Status unknown.

Timeline

13 September 2022

Primary endpoint
13 September 2022

1 February 2024

Quick facts

Lead sponsor	First Affiliated Hospital Xi'an Jiaotong University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	140
Start date	13 September 2022
Primary completion	13 September 2022
Estimated completion	1 February 2024
Sites	1 location across China

Drugs / interventions tested

Standard infusion chemotherapy — full drug profile →
BL - 5 ala PDT

Conditions studied

Non-muscle-invasive Bladder Cancer — all drugs for Non-muscle-invasive Bladder Cancer →

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Who can join

Adults 18 to 80, any sex, with Non-muscle-invasive Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project will conduct a large-sample, multi-center prospective clinical trial to further establish the safety and efficacy of BL-5ALA-PDT in preventing Non-Muscle Invasive Bladder Cancer (NMIBC) recurrence when compared to the usual postoperative perfusion chemotherapy regimen.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment.
Penetra M, Arnaut LG, Gomes-da-Silva LC. · · 2023 · cited 36× · PMID 37346450 · DOI 10.1080/2162402x.2023.2226535

Verify or expand the search:

Other recruiting trials for Non-muscle-invasive Bladder Cancer

Currently open trials in the same condition.

NCT05796375 — Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance · Phase 2 · recruiting
NCT07494864 — Effects of Microbiological and Immunological Factors on the Lower Urinary Tract · recruiting
NCT05519241 — A Phase I Intravesical PPM Therapy for NMIBC · Phase 1 · recruiting
NCT03528694 — Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasiv · Phase 3 · active not recruiting

Other First Affiliated Hospital Xi'an Jiaotong University trials

Trials by the same sponsor.

NCT07389460 — Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) · Phase 3 · not yet recruiting
NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
NCT07168291 — Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma · EARLY_PHASE1 · not yet recruiting
NCT06775782 — Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis · NA · recruiting
NCT07266467 — Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05547516 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital Xi'an Jiaotong University
Last refreshed: 21 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05547516.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing